Best hematologic and organ response to treatment
| Hematologic response-evaluable patients . | PI-naive cohort, n = 5 (%) . | PI-exposed cohort, n = 16 (%) . | RP2/3D cohort, N = 21 (%) . |
|---|---|---|---|
| ORR | 5 (100) | 6 (38) | 11 (52) |
| CR | 2 (40) | 0 | 2 (10)* |
| VGPR | 3 (60) | 4 (25) | 7 (33)† |
| PR | 0 | 2 (13) | 2 (10)* |
| No change | 0 | 9 (56) | 9 (43) |
| Progressive disease | 0 | 1 (6) | 1 (5) |
| Hematologic response-evaluable patients . | PI-naive cohort, n = 5 (%) . | PI-exposed cohort, n = 16 (%) . | RP2/3D cohort, N = 21 (%) . |
|---|---|---|---|
| ORR | 5 (100) | 6 (38) | 11 (52) |
| CR | 2 (40) | 0 | 2 (10)* |
| VGPR | 3 (60) | 4 (25) | 7 (33)† |
| PR | 0 | 2 (13) | 2 (10)* |
| No change | 0 | 9 (56) | 9 (43) |
| Progressive disease | 0 | 1 (6) | 1 (5) |
| Organ response-evaluable patients . | PI-naïve cohort, n = 5 (%) . | PI-exposed cohort, n = 13 (%) . | RP2/3D cohort, N = 18 (%) . |
|---|---|---|---|
| Response | 5 (100) | 5 (38) | 10 (56) |
| Cardiac response‡ | 2/3 (67)§ | 3/8 (38) | 5/11 (45) |
| Renal response¶ | 3/3 (100) | 2/8 (25) | 5/11 (45) |
| No change | 0 | 8 (62) | 8 (44) |
| Progression | 0 | 0 | 0 |
| Organ response-evaluable patients . | PI-naïve cohort, n = 5 (%) . | PI-exposed cohort, n = 13 (%) . | RP2/3D cohort, N = 18 (%) . |
|---|---|---|---|
| Response | 5 (100) | 5 (38) | 10 (56) |
| Cardiac response‡ | 2/3 (67)§ | 3/8 (38) | 5/11 (45) |
| Renal response¶ | 3/3 (100) | 2/8 (25) | 5/11 (45) |
| No change | 0 | 8 (62) | 8 (44) |
| Progression | 0 | 0 | 0 |
ORR indicates overall response rate; CR, complete response; PR, partial response; VGPR, very good partial response.
One patient received dexamethasone.
Two patients received dexamethasone.
According to NT-proBNP levels in 11 response-evaluable patients with cardiac involvement at baseline.
One additional patient had a cardiac response by echo.
Assessed retrospectively by updated renal response criteria36 in 11 response-evaluable patients with renal involvement at baseline.